{"disease":{"id":"gout-and-hyperuricemia","name":"gout and hyperuricemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07369622","title":"HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":228,"lead_sponsor_name":"Haiphong University of Medicine and Pharmacy","has_results":false},{"nct_id":"NCT02078219","title":"Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07498647","title":"Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"BioRay Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05513976","title":"Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":129,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06674109","title":"SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06196580","title":"PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}